top of page
The Professional Network for Healthcare Experts
Roche’s Genentech licenses Hanmi obesity candidate HM17321 in deal worth up to $2.3 billion
The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.
nuaxia
14 hours ago3 min read
Roche Secures CE Mark for Automated Blood Test to Detect Latent Tuberculosis
The Elecsys IGRA TB test delivers results in under 24 hours and brings automated latent tuberculosis screening to Roche's cobas immunoassay platforms.
nuaxia
Jul 102 min read
Roche Strengthens Breast Cancer Pipeline with $490m+ Astex Partnership
Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.
nuaxia
Jul 72 min read
Breaking the BTK Code: Roche Goes All-In on Degrader Strategy with $2.3B Nurix Deal
Roche has struck a deal worth up to $2.3bn with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an oral BTK degrader targeting B-cell malignancies, immunology, and neurology.
nuaxia
Jun 93 min read
FDA Approves Roche’s Tecentriq in First ctDNA-Guided Cancer Therapy
Landmark decision ties bladder cancer treatment to molecular residual disease testing
nuaxia
May 182 min read
bottom of page